MX2010012931A - Metodos para tratar una enfermedad asociada con quinesina meiotica. - Google Patents

Metodos para tratar una enfermedad asociada con quinesina meiotica.

Info

Publication number
MX2010012931A
MX2010012931A MX2010012931A MX2010012931A MX2010012931A MX 2010012931 A MX2010012931 A MX 2010012931A MX 2010012931 A MX2010012931 A MX 2010012931A MX 2010012931 A MX2010012931 A MX 2010012931A MX 2010012931 A MX2010012931 A MX 2010012931A
Authority
MX
Mexico
Prior art keywords
kinesin
agent
activity
hset
cell
Prior art date
Application number
MX2010012931A
Other languages
English (en)
Spanish (es)
Inventor
David Pellman
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of MX2010012931A publication Critical patent/MX2010012931A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2010012931A 2008-05-30 2009-05-28 Metodos para tratar una enfermedad asociada con quinesina meiotica. MX2010012931A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5759008P 2008-05-30 2008-05-30
PCT/US2009/045406 WO2009155025A1 (en) 2008-05-30 2009-05-28 Methods of treating a meiotic kinesin-associated disease

Publications (1)

Publication Number Publication Date
MX2010012931A true MX2010012931A (es) 2011-02-24

Family

ID=41110533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012931A MX2010012931A (es) 2008-05-30 2009-05-28 Metodos para tratar una enfermedad asociada con quinesina meiotica.

Country Status (12)

Country Link
US (3) US8629118B2 (https=)
EP (1) EP2315594B1 (https=)
JP (3) JP5735417B2 (https=)
KR (1) KR20110022000A (https=)
CN (1) CN102316877A (https=)
AU (1) AU2009260527A1 (https=)
BR (1) BRPI0912043A2 (https=)
CA (1) CA2725911A1 (https=)
EA (1) EA201071422A1 (https=)
ES (1) ES2633930T3 (https=)
MX (1) MX2010012931A (https=)
WO (1) WO2009155025A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
CN102316877A (zh) 2008-05-30 2012-01-11 达那-法伯癌症研究所 治疗减数分裂驱动蛋白相关疾病的方法
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US20150309031A2 (en) * 2013-12-05 2015-10-29 Novazoi Theranostics Compositions and methods for prognosis and treatment of cancer
US9589100B2 (en) * 2014-02-28 2017-03-07 Novazoi Theranostics Method for determining the risk profile of neoplastic tissue
CN113456633A (zh) * 2021-06-11 2021-10-01 广西医科大学 红海海绵素a在制备抗肺癌侵袭转移药物中的应用
WO2023131690A1 (en) 2022-01-10 2023-07-13 Merck Patent Gmbh Substituted heterocycles as hset inhibitors
CN115327125A (zh) * 2022-07-14 2022-11-11 宁波大学 一种蛋白质inf2在制备肝癌诊断标志物中的应用
CN120265629A (zh) 2022-11-07 2025-07-04 默克专利股份公司 被取代的双环和三环hset抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6410254B1 (en) * 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
WO2000063353A1 (en) * 1999-04-20 2000-10-26 Cytokinetics Human kinesins and methods of producing and purifying human kinesins
US6743599B1 (en) * 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) * 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7416856B2 (en) * 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
IL158083A0 (en) 2001-03-29 2004-03-28 Bristol Myers Squibb Co A PHARMACEUTICAL COMPOSITION CONTAINING AN Eg5 PROTEIN INHIBITOR
US20040009156A1 (en) 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7163927B2 (en) 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20070026424A1 (en) 2005-04-15 2007-02-01 Powell Charles A Gene profiles correlating with histology and prognosis
AR062200A1 (es) 2006-08-04 2008-10-22 Aeterna Zentaris Gmbh Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas
US20080051463A1 (en) * 2006-08-04 2008-02-28 Aeterna Zentaris Gmbh Anthracene compounds and their use for treating benign and malignant tumor disorders
US20100145131A1 (en) 2007-05-01 2010-06-10 Helena Grinberg-Rashi Methods and kits for predicting cancer metastasis
CN102316877A (zh) 2008-05-30 2012-01-11 达那-法伯癌症研究所 治疗减数分裂驱动蛋白相关疾病的方法

Also Published As

Publication number Publication date
US20140106344A1 (en) 2014-04-17
JP2016169224A (ja) 2016-09-23
BRPI0912043A2 (pt) 2019-09-24
JP2015131813A (ja) 2015-07-23
WO2009155025A1 (en) 2009-12-23
US20110190374A1 (en) 2011-08-04
AU2009260527A1 (en) 2009-12-23
EA201071422A1 (ru) 2011-08-30
JP2011525174A (ja) 2011-09-15
US20150111786A1 (en) 2015-04-23
US9645136B2 (en) 2017-05-09
US8962592B2 (en) 2015-02-24
KR20110022000A (ko) 2011-03-04
ES2633930T3 (es) 2017-09-26
JP5735417B2 (ja) 2015-06-17
EP2315594A1 (en) 2011-05-04
US8629118B2 (en) 2014-01-14
JP6132409B2 (ja) 2017-05-24
CN102316877A (zh) 2012-01-11
CA2725911A1 (en) 2009-12-23
JP6184556B2 (ja) 2017-08-23
EP2315594B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
Inoki et al. TSC2 mediates cellular energy response to control cell growth and survival
Chopra et al. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics
Rao et al. Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2
Infante et al. Itch/β-arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis
MX2010012931A (es) Metodos para tratar una enfermedad asociada con quinesina meiotica.
Cho et al. AMPK and endothelial nitric oxide synthase signaling regulates K-Ras plasma membrane interactions via cyclic GMP-dependent protein kinase 2
Jiang et al. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCβII messenger ribonucleic acid
Tan et al. Ari-1 regulates myonuclear organization together with parkin and is associated with aortic aneurysms
Liu et al. Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors
US20100267626A1 (en) Methods and compositions for measuring wnt activation and for treating wnt-related cancers
Illing et al. Heterologous regulation of agonist‐independent μ‐opioid receptor phosphorylation by protein kinase C
Yoshida et al. CDC6 interaction with ATR regulates activation of a replication checkpoint in higher eukaryotic cells
Peschiaroli et al. The ubiquitin-specific protease USP47 is a novel β-TRCP interactor regulating cell survival
Thompson et al. An inhibitor of PIDDosome formation
Ito et al. Cloning and characterization of diacylglycerol kinase ι splice variants in rat brain
Ling et al. Diallyl disulfide selectively causes checkpoint kinase-1 mediated G2/M arrest in human MGC803 gastric cancer cell line
Vogt et al. Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells
Wang et al. EWSR1 regulates mitosis by dynamically influencing microtubule acetylation
Cho et al. The cAMP signaling system inhibits the repair of γ-ray-induced DNA damage by promoting Epac1-mediated proteasomal degradation of XRCC1 protein in human lung cancer cells
Danielsen et al. HCLK2 is required for activity of the DNA damage response kinase ATR
Salian-Mehta et al. Novel interaction of class IIb histone deacetylase 6 (HDAC6) with class IIa HDAC9 controls gonadotropin releasing hormone (GnRH) neuronal cell survival and movement
Chen et al. The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis
US20140314788A1 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto
Joglekar et al. PKC-alpha promotes phosphorylation of KRAS suppressing its oncogenic properties
De Benedetti et al. Targeting the TLK1/NEK1 Axis in PCa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal